Pharmaceuticals, Biotechnology and Life Sciences
Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia…
In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp…
Novel Endoscopic Procedure Demonstrates Substantial and Durable Reduction in Insulin Resistance and Improvement in Beta Cell Function for People with…
Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual…
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will…
FREEHOLD, N.J., May 01, 2025 (GLOBE NEWSWIRE) — Channel Therapeutics Corporation, (“Channel” or the “Company”), (NYSE American: CHRO), a pioneer…
NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration…
OBI-902 is the first ADC utilizing OBI’s proprietary GlycOBI® ADC enabling technologyTAIPEI, Taiwan, May 01, 2025 (GLOBE NEWSWIRE) — OBI…
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental Glomerulosclerosis (FSGS) DMX-200 is in a pivotal…
Tokyo, Japan and Cambridge, UK, 1 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today…